Depomed Inc (NASDAQ:DEPO): Jeffrey Smith’s Starboard Value LP filed an amended 13D.
You can check out Starboard Value LP’s latest holdings and filings here.
Please follow Starboard Value LP (if you aren’t already doing so) to get real-time email alerts whenever we publish an article about Starboard Value LP or update its stock holdings.
Follow Jeff Smith's Starboard Value LP
You can access the original SEC filing by clicking here.
Ownership Summary Table
Name | Sole Voting Power | Shared Voting Power | Sole Dispositive Power | Shared Dispositive Power | Aggregate Amount Owned Power | Percent of Class |
---|---|---|---|---|---|---|
STARBOARD VALUE | 4,735,295 | 4,735,295 | 4,735,295 | 4,735,295 | 7.5% | |
STARBOARD VALUE AND OPPORTUNITY MASTER FUND LTD | 3,651,714 | 3,651,714 | 4,735,295 | 3,651,714 | 5.7% | |
STARBOARD VALUE AND OPPORTUNITY S | 430,843 | 430,843 | 4,735,295 | 430,843 | Less than 1% | |
STARBOARD VALUE AND OPPORTUNITY C | 239,310 | 239,310 | 239,310 | Less than 1% | ||
STARBOARD VALUE R | 239,310 | 239,310 | 239,310 | Less than 1% | ||
STARBOARD VALUE R GP | 239,310 | 239,310 | 239,310 | Less than 1% | ||
STARBOARD VALUE GP | 4,735,295 | 4,735,295 | 4,735,295 | 7.5% | ||
STARBOARD PRINCIPAL CO | 4,735,295 | 4,735,295 | 4,735,295 | 7.5% | ||
STARBOARD PRINCIPAL CO GP | 4,735,295 | 4,735,295 | 4,735,295 | 7.5% | ||
JEFFREY C. SMITH | 3,252 | 3,252 | 4,735,295 | 7.5% | ||
MARK R. MITCHELL | 4,735,295 | 7.5% | ||||
PETER A. FELD | 4,735,295 | 7.5% | ||||
GAVIN T. MOLINELLI | 3,252 | Less than 1% |
Follow Jeff Smith's Starboard Value LP
Page 1 of 23 – SEC Filing
UNITED STATES
SECURITIES AND EXCHANGE
COMMISSION
Washington, D.C. 20549
SCHEDULE 13D
(Rule 13d-101)
INFORMATION TO BE INCLUDED
IN STATEMENTS FILED PURSUANT
TO § 240.13d-1(a)
AND AMENDMENTS THERETO FILED PURSUANT TO
§ 240.13d-2(a)
(Amendment No. 9)1
Depomed, Inc.
(Name
of Issuer)
Common Stock,
no par value
(Title of Class of Securities)
249908104
(CUSIP Number)
JEFFREY
C. SMITH
STARBOARD
VALUE LP
777 Third Avenue, 18th Floor
New York, New York 10017
(212) 845-7977
STEVE WOLOSKY, ESQ.
OLSHAN FROME WOLOSKY LLP
1325 Avenue of the Americas
New York, New York 10019
(212) 451-2300
(Name, Address and Telephone Number of Person
Authorized to Receive Notices
and Communications)
April 3, 2018
(Date of Event Which Requires
Filing of This Statement)
If
the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule
13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following
box ¨.
Note: Schedules
filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See
§ 240.13d-7 for other parties to whom copies are to be sent.
1
The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to
the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided
in a prior cover page.
The information required
on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities
Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject
to all other provisions of the Act (however, see the Notes).
Follow Assertio Therapeutics Inc (NASDAQ:ASRT)
Follow Assertio Therapeutics Inc (NASDAQ:ASRT)
Page 2 of 23 – SEC Filing
1 | NAME OF REPORTING PERSON | ||||||||||||||||||
STARBOARD VALUE LP | |||||||||||||||||||
2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP | (a) ☐ | |||||||||||||||||
(b) ☐ | |||||||||||||||||||
3 | SEC USE ONLY | ||||||||||||||||||
4 | SOURCE OF FUNDS | ||||||||||||||||||
OO | |||||||||||||||||||
5 | CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e) | ☐ | |||||||||||||||||
6 | CITIZENSHIP OR PLACE OF ORGANIZATION | ||||||||||||||||||
DELAWARE | |||||||||||||||||||
NUMBER OF | 7 | SOLE VOTING POWER | |||||||||||||||||
SHARES | |||||||||||||||||||
BENEFICIALLY | 4,735,295 | ||||||||||||||||||
OWNED BY | 8 | SHARED VOTING POWER | |||||||||||||||||
EACH | |||||||||||||||||||
REPORTING | – 0 – | ||||||||||||||||||
PERSON WITH | 9 | SOLE DISPOSITIVE POWER | |||||||||||||||||
4,735,295 | |||||||||||||||||||
10 | SHARED DISPOSITIVE POWER | ||||||||||||||||||
– 0 – | |||||||||||||||||||
11 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON | ||||||||||||||||||
4,735,295* | |||||||||||||||||||
12 | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES | ☐ | |||||||||||||||||
13 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) | ||||||||||||||||||
7.5% | |||||||||||||||||||
14 | TYPE OF REPORTING PERSON | ||||||||||||||||||
PN |
* Includes 194,730 Shares underlying certain
forward purchase contracts exercisable within 60 days hereof.
2 |
Follow Assertio Therapeutics Inc (NASDAQ:ASRT)
Follow Assertio Therapeutics Inc (NASDAQ:ASRT)
Page 3 of 23 – SEC Filing
1 | NAME OF REPORTING PERSON | ||||||||||||||||||
STARBOARD VALUE AND OPPORTUNITY MASTER FUND LTD | |||||||||||||||||||
2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP | (a) ☐ | |||||||||||||||||
(b) ☐ | |||||||||||||||||||
3 | SEC USE ONLY | ||||||||||||||||||
4 | SOURCE OF FUNDS | ||||||||||||||||||
WC | |||||||||||||||||||
5 | CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e) | ☐ | |||||||||||||||||
6 | CITIZENSHIP OR PLACE OF ORGANIZATION | ||||||||||||||||||
CAYMAN ISLANDS | |||||||||||||||||||
NUMBER OF | 7 | SOLE VOTING POWER | |||||||||||||||||
SHARES | |||||||||||||||||||
BENEFICIALLY | 3,651,714 | ||||||||||||||||||
OWNED BY | 8 | SHARED VOTING POWER | |||||||||||||||||
EACH | |||||||||||||||||||
REPORTING | – 0 – | ||||||||||||||||||
PERSON WITH | 9 | SOLE DISPOSITIVE POWER | |||||||||||||||||
3,651,714 | |||||||||||||||||||
10 | SHARED DISPOSITIVE POWER | ||||||||||||||||||
– 0 – | |||||||||||||||||||
11 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON | ||||||||||||||||||
3,651,714* | |||||||||||||||||||
12 | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES | ☐ | |||||||||||||||||
13 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) | ||||||||||||||||||
5.7% | |||||||||||||||||||
14 | TYPE OF REPORTING PERSON | ||||||||||||||||||
CO |
* Includes 194,730 Shares underlying certain
forward purchase contracts exercisable within 60 days hereof.
3 |
Follow Assertio Therapeutics Inc (NASDAQ:ASRT)
Follow Assertio Therapeutics Inc (NASDAQ:ASRT)
Page 4 of 23 – SEC Filing
1 | NAME OF REPORTING PERSON | ||||||||||||||||||
STARBOARD VALUE AND OPPORTUNITY S LLC | |||||||||||||||||||
2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP | (a) ☐ | |||||||||||||||||
(b) ☐ | |||||||||||||||||||
3 | SEC USE ONLY | ||||||||||||||||||
4 | SOURCE OF FUNDS | ||||||||||||||||||
WC | |||||||||||||||||||
5 | CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e) | ☐ | |||||||||||||||||
6 | CITIZENSHIP OR PLACE OF ORGANIZATION | ||||||||||||||||||
DELAWARE | |||||||||||||||||||
NUMBER OF | 7 | SOLE VOTING POWER | |||||||||||||||||
SHARES | |||||||||||||||||||
BENEFICIALLY | 430,843 | ||||||||||||||||||
OWNED BY | 8 | SHARED VOTING POWER | |||||||||||||||||
EACH | |||||||||||||||||||
REPORTING | – 0 – | ||||||||||||||||||
PERSON WITH | 9 | SOLE DISPOSITIVE POWER | |||||||||||||||||
430,843 | |||||||||||||||||||
10 | SHARED DISPOSITIVE POWER | ||||||||||||||||||
– 0 – | |||||||||||||||||||
11 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON | ||||||||||||||||||
430,843 | |||||||||||||||||||
12 | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES | ☐ | |||||||||||||||||
13 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) | ||||||||||||||||||
Less than 1% | |||||||||||||||||||
14 | TYPE OF REPORTING PERSON | ||||||||||||||||||
OO |
4 |
Follow Assertio Therapeutics Inc (NASDAQ:ASRT)
Follow Assertio Therapeutics Inc (NASDAQ:ASRT)
Page 5 of 23 – SEC Filing
1 | NAME OF REPORTING PERSON | ||||||||||||||||||
STARBOARD VALUE AND OPPORTUNITY C LP | |||||||||||||||||||
2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP | (a) ☐ | |||||||||||||||||
(b) ☐ | |||||||||||||||||||
3 | SEC USE ONLY | ||||||||||||||||||
4 | SOURCE OF FUNDS | ||||||||||||||||||
WC | |||||||||||||||||||
5 | CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e) | ☐ | |||||||||||||||||
6 | CITIZENSHIP OR PLACE OF ORGANIZATION | ||||||||||||||||||
DELAWARE | |||||||||||||||||||
NUMBER OF | 7 | SOLE VOTING POWER | |||||||||||||||||
SHARES | |||||||||||||||||||
BENEFICIALLY | 239,310 | ||||||||||||||||||
OWNED BY | 8 | SHARED VOTING POWER | |||||||||||||||||
EACH | |||||||||||||||||||
REPORTING | – 0 – | ||||||||||||||||||
PERSON WITH | 9 | SOLE DISPOSITIVE POWER | |||||||||||||||||
239,310 | |||||||||||||||||||
10 | SHARED DISPOSITIVE POWER | ||||||||||||||||||
– 0 – | |||||||||||||||||||
11 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON | ||||||||||||||||||
239,310 | |||||||||||||||||||
12 | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES | ☐ | |||||||||||||||||
13 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) | ||||||||||||||||||
Less than 1% | |||||||||||||||||||
14 | TYPE OF REPORTING PERSON | ||||||||||||||||||
PN |
5 |
Follow Assertio Therapeutics Inc (NASDAQ:ASRT)
Follow Assertio Therapeutics Inc (NASDAQ:ASRT)
Page 6 of 23 – SEC Filing
1 | NAME OF REPORTING PERSON | ||||||||||||||||||
STARBOARD VALUE R LP | |||||||||||||||||||
2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP | (a) ☐ | |||||||||||||||||
(b) ☐ | |||||||||||||||||||
3 | SEC USE ONLY | ||||||||||||||||||
4 | SOURCE OF FUNDS | ||||||||||||||||||
OO | |||||||||||||||||||
5 | CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e) | ☐ | |||||||||||||||||
6 | CITIZENSHIP OR PLACE OF ORGANIZATION | ||||||||||||||||||
DELAWARE | |||||||||||||||||||
NUMBER OF | 7 | SOLE VOTING POWER | |||||||||||||||||
SHARES | |||||||||||||||||||
BENEFICIALLY | 239,310 | ||||||||||||||||||
OWNED BY | 8 | SHARED VOTING POWER | |||||||||||||||||
EACH | |||||||||||||||||||
REPORTING | – 0 – | ||||||||||||||||||
PERSON WITH | 9 | SOLE DISPOSITIVE POWER | |||||||||||||||||
239,310 | |||||||||||||||||||
10 | SHARED DISPOSITIVE POWER | ||||||||||||||||||
– 0 – | |||||||||||||||||||
11 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON | ||||||||||||||||||
239,310 | |||||||||||||||||||
12 | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES | ☐ | |||||||||||||||||
13 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) | ||||||||||||||||||
Less than 1% | |||||||||||||||||||
14 | TYPE OF REPORTING PERSON | ||||||||||||||||||
PN |
6 |
Follow Assertio Therapeutics Inc (NASDAQ:ASRT)
Follow Assertio Therapeutics Inc (NASDAQ:ASRT)
Page 7 of 23 – SEC Filing
1 | NAME OF REPORTING PERSON | ||||||||||||||||||
STARBOARD VALUE R GP LLC | |||||||||||||||||||
2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP | (a) ☐ | |||||||||||||||||
(b) ☐ | |||||||||||||||||||
3 | SEC USE ONLY | ||||||||||||||||||
4 | SOURCE OF FUNDS | ||||||||||||||||||
OO | |||||||||||||||||||
5 | CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e) | ☐ | |||||||||||||||||
6 | CITIZENSHIP OR PLACE OF ORGANIZATION | ||||||||||||||||||
DELAWARE | |||||||||||||||||||
NUMBER OF | 7 | SOLE VOTING POWER | |||||||||||||||||
SHARES | |||||||||||||||||||
BENEFICIALLY | 239,310 | ||||||||||||||||||
OWNED BY | 8 | SHARED VOTING POWER | |||||||||||||||||
EACH | |||||||||||||||||||
REPORTING | – 0 – | ||||||||||||||||||
PERSON WITH | 9 | SOLE DISPOSITIVE POWER | |||||||||||||||||
239,310 | |||||||||||||||||||
10 | SHARED DISPOSITIVE POWER | ||||||||||||||||||
– 0 – | |||||||||||||||||||
11 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON | ||||||||||||||||||
239,310 | |||||||||||||||||||
12 | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES | ☐ | |||||||||||||||||
13 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) | ||||||||||||||||||
Less than 1% | |||||||||||||||||||
14 | TYPE OF REPORTING PERSON | ||||||||||||||||||
OO |
7 |
Follow Assertio Therapeutics Inc (NASDAQ:ASRT)
Follow Assertio Therapeutics Inc (NASDAQ:ASRT)
Page 8 of 23 – SEC Filing
1 | NAME OF REPORTING PERSON | ||||||||||||||||||
STARBOARD VALUE GP LLC | |||||||||||||||||||
2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP | (a) ☐ | |||||||||||||||||
(b) ☐ | |||||||||||||||||||
3 | SEC USE ONLY | ||||||||||||||||||
4 | SOURCE OF FUNDS | ||||||||||||||||||
OO | |||||||||||||||||||
5 | CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e) | ☐ | |||||||||||||||||
6 | CITIZENSHIP OR PLACE OF ORGANIZATION | ||||||||||||||||||
DELAWARE | |||||||||||||||||||
NUMBER OF | 7 | SOLE VOTING POWER | |||||||||||||||||
SHARES | |||||||||||||||||||
BENEFICIALLY | 4,735,295 | ||||||||||||||||||
OWNED BY | 8 | SHARED VOTING POWER | |||||||||||||||||
EACH | |||||||||||||||||||
REPORTING | – 0 – | ||||||||||||||||||
PERSON WITH | 9 | SOLE DISPOSITIVE POWER | |||||||||||||||||
4,735,295 | |||||||||||||||||||
10 | SHARED DISPOSITIVE POWER | ||||||||||||||||||
– 0 – | |||||||||||||||||||
11 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON | ||||||||||||||||||
4,735,295* | |||||||||||||||||||
12 | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES | ☐ | |||||||||||||||||
13 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) | ||||||||||||||||||
7.5% | |||||||||||||||||||
14 | TYPE OF REPORTING PERSON | ||||||||||||||||||
OO |
* Includes 194,730 Shares underlying certain
forward purchase contracts exercisable within 60 days hereof.
8 |
Follow Assertio Therapeutics Inc (NASDAQ:ASRT)
Follow Assertio Therapeutics Inc (NASDAQ:ASRT)
Page 9 of 23 – SEC Filing
1 | NAME OF REPORTING PERSON | ||||||||||||||||||
STARBOARD PRINCIPAL CO LP | |||||||||||||||||||
2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP | (a) ☐ | |||||||||||||||||
(b) ☐ | |||||||||||||||||||
3 | SEC USE ONLY | ||||||||||||||||||
4 | SOURCE OF FUNDS | ||||||||||||||||||
OO | |||||||||||||||||||
5 | CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e) | ☐ | |||||||||||||||||
6 | CITIZENSHIP OR PLACE OF ORGANIZATION | ||||||||||||||||||
DELAWARE | |||||||||||||||||||
NUMBER OF | 7 | SOLE VOTING POWER | |||||||||||||||||
SHARES | |||||||||||||||||||
BENEFICIALLY | 4,735,295 | ||||||||||||||||||
OWNED BY | 8 | SHARED VOTING POWER | |||||||||||||||||
EACH | |||||||||||||||||||
REPORTING | – 0 – | ||||||||||||||||||
PERSON WITH | 9 | SOLE DISPOSITIVE POWER | |||||||||||||||||
4,735,295 | |||||||||||||||||||
10 | SHARED DISPOSITIVE POWER | ||||||||||||||||||
– 0 – | |||||||||||||||||||
11 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON | ||||||||||||||||||
4,735,295* | |||||||||||||||||||
12 | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES | ☐ | |||||||||||||||||
13 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) | ||||||||||||||||||
7.5% | |||||||||||||||||||
14 | TYPE OF REPORTING PERSON | ||||||||||||||||||
PN |
* Includes 194,730 Shares underlying certain
forward purchase contracts exercisable within 60 days hereof.
9 |
Follow Assertio Therapeutics Inc (NASDAQ:ASRT)
Follow Assertio Therapeutics Inc (NASDAQ:ASRT)
Page 10 of 23 – SEC Filing
1 | NAME OF REPORTING PERSON | ||||||||||||||||||
STARBOARD PRINCIPAL CO GP LLC | |||||||||||||||||||
2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP | (a) ☐ | |||||||||||||||||
(b) ☐ | |||||||||||||||||||
3 | SEC USE ONLY | ||||||||||||||||||
4 | SOURCE OF FUNDS | ||||||||||||||||||
OO | |||||||||||||||||||
5 | CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e) | ☐ | |||||||||||||||||
6 | CITIZENSHIP OR PLACE OF ORGANIZATION | ||||||||||||||||||
DELAWARE | |||||||||||||||||||
NUMBER OF | 7 | SOLE VOTING POWER | |||||||||||||||||
SHARES | |||||||||||||||||||
BENEFICIALLY | 4,735,295 | ||||||||||||||||||
OWNED BY | 8 | SHARED VOTING POWER | |||||||||||||||||
EACH | |||||||||||||||||||
REPORTING | – 0 – | ||||||||||||||||||
PERSON WITH | 9 | SOLE DISPOSITIVE POWER | |||||||||||||||||
4,735,295 | |||||||||||||||||||
10 | SHARED DISPOSITIVE POWER | ||||||||||||||||||
– 0 – | |||||||||||||||||||
11 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON | ||||||||||||||||||
4,735,295* | |||||||||||||||||||
12 | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES | ☐ | |||||||||||||||||
13 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) | ||||||||||||||||||
7.5% | |||||||||||||||||||
14 | TYPE OF REPORTING PERSON | ||||||||||||||||||
OO |
* Includes 194,730 Shares underlying certain
forward purchase contracts exercisable within 60 days hereof.
10 |
Follow Assertio Therapeutics Inc (NASDAQ:ASRT)
Follow Assertio Therapeutics Inc (NASDAQ:ASRT)
Page 11 of 23 – SEC Filing
1 | NAME OF REPORTING PERSON | ||||||||||||||||||
JEFFREY C. SMITH | |||||||||||||||||||
2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP | (a) ☐ | |||||||||||||||||
(b) ☐ | |||||||||||||||||||
3 | SEC USE ONLY | ||||||||||||||||||
4 | SOURCE OF FUNDS | ||||||||||||||||||
OO | |||||||||||||||||||
5 | CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e) | ☐ | |||||||||||||||||
6 | CITIZENSHIP OR PLACE OF ORGANIZATION | ||||||||||||||||||
USA | |||||||||||||||||||
NUMBER OF | 7 | SOLE VOTING POWER | |||||||||||||||||
SHARES | |||||||||||||||||||
BENEFICIALLY | – 0 – | ||||||||||||||||||
OWNED BY | 8 | SHARED VOTING POWER | |||||||||||||||||
EACH | |||||||||||||||||||
REPORTING | 4,735,295 | ||||||||||||||||||
PERSON WITH | 9 | SOLE DISPOSITIVE POWER | |||||||||||||||||
– 0 – | |||||||||||||||||||
10 | SHARED DISPOSITIVE POWER | ||||||||||||||||||
4,735,295 | |||||||||||||||||||
11 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON | ||||||||||||||||||
4,735,295* | |||||||||||||||||||
12 | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES | ☐ | |||||||||||||||||
13 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) | ||||||||||||||||||
7.5% | |||||||||||||||||||
14 | TYPE OF REPORTING PERSON | ||||||||||||||||||
IN |
* Includes 194,730 Shares underlying certain
forward purchase contracts exercisable within 60 days hereof.
11 |
Follow Assertio Therapeutics Inc (NASDAQ:ASRT)
Follow Assertio Therapeutics Inc (NASDAQ:ASRT)
Page 12 of 23 – SEC Filing
1 | NAME OF REPORTING PERSON | ||||||||||||||||||
MARK R. MITCHELL | |||||||||||||||||||
2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP | (a) ☐ | |||||||||||||||||
(b) ☐ | |||||||||||||||||||
3 | SEC USE ONLY | ||||||||||||||||||
4 | SOURCE OF FUNDS | ||||||||||||||||||
OO | |||||||||||||||||||
5 | CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e) | ☐ | |||||||||||||||||
6 | CITIZENSHIP OR PLACE OF ORGANIZATION | ||||||||||||||||||
USA | |||||||||||||||||||
NUMBER OF | 7 | SOLE VOTING POWER | |||||||||||||||||
SHARES | |||||||||||||||||||
BENEFICIALLY | – 0 – | ||||||||||||||||||
OWNED BY | 8 | SHARED VOTING POWER | |||||||||||||||||
EACH | |||||||||||||||||||
REPORTING | 4,735,295 | ||||||||||||||||||
PERSON WITH | 9 | SOLE DISPOSITIVE POWER | |||||||||||||||||
– 0 – | |||||||||||||||||||
10 | SHARED DISPOSITIVE POWER | ||||||||||||||||||
4,735,295 | |||||||||||||||||||
11 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON | ||||||||||||||||||
4,735,295* | |||||||||||||||||||
12 | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES | ☐ | |||||||||||||||||
13 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) | ||||||||||||||||||
7.5% | |||||||||||||||||||
14 | TYPE OF REPORTING PERSON | ||||||||||||||||||
IN |
* Includes 194,730 Shares underlying certain
forward purchase contracts exercisable within 60 days hereof.
12 |
Follow Assertio Therapeutics Inc (NASDAQ:ASRT)
Follow Assertio Therapeutics Inc (NASDAQ:ASRT)
Page 13 of 23 – SEC Filing
1 | NAME OF REPORTING PERSON | ||||||||||||||||||
PETER A. FELD | |||||||||||||||||||
2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP | (a) ☐ | |||||||||||||||||
(b) ☐ | |||||||||||||||||||
3 | SEC USE ONLY | ||||||||||||||||||
4 | SOURCE OF FUNDS | ||||||||||||||||||
OO | |||||||||||||||||||
5 | CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e) | ☐ | |||||||||||||||||
6 | CITIZENSHIP OR PLACE OF ORGANIZATION | ||||||||||||||||||
USA | |||||||||||||||||||
NUMBER OF | 7 | SOLE VOTING POWER | |||||||||||||||||
SHARES | |||||||||||||||||||
BENEFICIALLY | – 0 – | ||||||||||||||||||
OWNED BY | 8 | SHARED VOTING POWER | |||||||||||||||||
EACH | |||||||||||||||||||
REPORTING | 4,735,295 | ||||||||||||||||||
PERSON WITH | 9 | SOLE DISPOSITIVE POWER | |||||||||||||||||
– 0 – | |||||||||||||||||||
10 | SHARED DISPOSITIVE POWER | ||||||||||||||||||
4,735,295 | |||||||||||||||||||
11 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON | ||||||||||||||||||
4,735,295* | |||||||||||||||||||
12 | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES | ☐ | |||||||||||||||||
13 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) | ||||||||||||||||||
7.5% | |||||||||||||||||||
14 | TYPE OF REPORTING PERSON | ||||||||||||||||||
IN |
* Includes 194,730 Shares underlying certain
forward purchase contracts exercisable within 60 days hereof.
13 |
Follow Assertio Therapeutics Inc (NASDAQ:ASRT)
Follow Assertio Therapeutics Inc (NASDAQ:ASRT)
Page 14 of 23 – SEC Filing
1 | NAME OF REPORTING PERSON | ||||||||||||||||||
GAVIN T. MOLINELLI | |||||||||||||||||||
2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP | (a) ☐ | |||||||||||||||||
(b) ☐ | |||||||||||||||||||
3 | SEC USE ONLY | ||||||||||||||||||
4 | SOURCE OF FUNDS | ||||||||||||||||||
OO | |||||||||||||||||||
5 | CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e) | ☐ | |||||||||||||||||
6 | CITIZENSHIP OR PLACE OF ORGANIZATION | ||||||||||||||||||
USA | |||||||||||||||||||
NUMBER OF | 7 | SOLE VOTING POWER | |||||||||||||||||
SHARES | |||||||||||||||||||
BENEFICIALLY | 3,252 | ||||||||||||||||||
OWNED BY | 8 | SHARED VOTING POWER | |||||||||||||||||
EACH | |||||||||||||||||||
REPORTING | – 0 – | ||||||||||||||||||
PERSON WITH | 9 | SOLE DISPOSITIVE POWER | |||||||||||||||||
3,252 | |||||||||||||||||||
10 | SHARED DISPOSITIVE POWER | ||||||||||||||||||
– 0 – | |||||||||||||||||||
11 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON | ||||||||||||||||||
3,252 | |||||||||||||||||||
12 | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES | ☐ | |||||||||||||||||
13 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) | ||||||||||||||||||
Less than 1% | |||||||||||||||||||
14 | TYPE OF REPORTING PERSON | ||||||||||||||||||
IN |
14 |
Follow Assertio Therapeutics Inc (NASDAQ:ASRT)
Follow Assertio Therapeutics Inc (NASDAQ:ASRT)
Page 15 of 23 – SEC Filing
The following constitutes
Amendment No. 9 to the Schedule 13D filed by the undersigned (“Amendment No. 9”). This Amendment No. 9 amends the Schedule
13D as specifically set forth herein.
Item 3. | Source and Amount of Funds or Other Consideration. |
Item 3 is hereby amended
and restated to read as follows:
The Shares purchased
by each of Starboard V&O Fund, Starboard S LLC and Starboard C LP and held in the Starboard Value LP Account were purchased
with working capital (which may, at any given time, include margin loans made by brokerage firms in the ordinary course of business)
in open market purchases, except as otherwise noted, as set forth in Schedule A, which is incorporated by reference herein. The
aggregate purchase price of the 3,456,984 Shares beneficially owned by Starboard V&O Fund is approximately $50,015,287, excluding
brokerage commissions. The aggregate purchase price of the entered into over-the-counter forward purchase contracts providing for
the purchase of 194,730 Shares by Starboard V&O Fund is approximately $3,504,653, excluding commissions. The aggregate purchase
price of the 430,843 Shares beneficially owned by Starboard S LLC is approximately $6,393,502, excluding brokerage commissions.
The aggregate purchase price of the 239,310 Shares beneficially owned by Starboard C LP is approximately $3,484,167, excluding
brokerage commissions. The aggregate purchase price of the 413,428 Shares held in the Starboard Value LP Account is approximately
$6,204,115, excluding brokerage commissions. The 3,252 Shares beneficially owned by Mr. Molinelli represent shares that were granted
to Mr. Molinelli by the Issuer in his former capacity as a director of the Issuer.
Item 5. | Interest in Securities of the Issuer. |
Items 5(a) – (c) are hereby amended
and restated to read as follows:
The aggregate percentage
of Shares reported owned by each person named herein is based upon 63,516,077 Shares outstanding, as of March 16, 2018, which is
the total number of Shares outstanding as reported in the Issuer’s definitive proxy statement on Schedule 14A filed with
the Securities and Exchange Commission on March 27, 2018.
A. | Starboard V&O Fund |
(a) | As of the close of business on April 5, 2018, Starboard V&O Fund beneficially owned 3,651,714 Shares, including 194,730 Shares underlying certain forward purchase contracts. |
Percentage: Approximately 5.7%
(b) | 1. Sole power to vote or direct vote: 3,651,714 2. Shared power to vote or direct vote: 0 3. Sole power to dispose or direct the disposition: 3,651,714 4. Shared power to dispose or direct the disposition: 0 |
(c) | The transactions in the Shares by Starboard V&O Fund since the filing of Amendment No. 8 to the Schedule 13D are set forth in Schedule A and are incorporated herein by reference. |
15 |
Follow Assertio Therapeutics Inc (NASDAQ:ASRT)
Follow Assertio Therapeutics Inc (NASDAQ:ASRT)
Page 16 of 23 – SEC Filing
B. | Starboard S LLC |
(a) | As of the close of business on April 5, 2018, Starboard S LLC beneficially owned 430,843 Shares. |
Percentage: Less than 1%
(b) | 1. Sole power to vote or direct vote: 430,843 2. Shared power to vote or direct vote: 0 3. Sole power to dispose or direct the disposition: 430,843 4. Shared power to dispose or direct the disposition: 0 |
(c) | The transactions in the Shares by Starboard S LLC since the filing of Amendment No. 8 to the Schedule 13D are set forth in Schedule A and are incorporated herein by reference. |
C. | Starboard C LP |
(a) | As of the close of business on April 5, 2018, Starboard C LP beneficially owned 239,310 Shares. |
Percentage: Less than 1%
(b) | 1. Sole power to vote or direct vote: 239,310 2. Shared power to vote or direct vote: 0 3. Sole power to dispose or direct the disposition: 239,310 4. Shared power to dispose or direct the disposition: 0 |
(c) | The transactions in the Shares by Starboard C LP since the filing of Amendment No. 8 to the Schedule 13D are set forth in Schedule A and are incorporated herein by reference. |
D. | Starboard R LP |
(a) | Starboard R LP, as the general partner of Starboard C LP, may be deemed the beneficial owner of the 239,310 shares owned by Starboard C LP. |
Percentage: Less than 1%
(b) | 1. Sole power to vote or direct vote: 239,310 2. Shared power to vote or direct vote: 0 3. Sole power to dispose or direct the disposition: 239,310 4. Shared power to dispose or direct the disposition: 0 |
(c) | Starboard R LP has not entered into any transactions in the Shares since the filing of Amendment No. 8 to the Schedule 13D. The transactions in the Shares on behalf of Starboard C LP since the filing of Amendment No. 8 to the Schedule 13D are set forth in Schedule A and are incorporated herein by reference. |
E. | Starboard R GP |
(a) | Starboard R GP, as the general partner of Starboard R LP, may be deemed the beneficial owner of the 239,310 shares owned by Starboard C LP. |
Percentage: Less than 1%
16 |
Follow Assertio Therapeutics Inc (NASDAQ:ASRT)
Follow Assertio Therapeutics Inc (NASDAQ:ASRT)
Page 17 of 23 – SEC Filing
(b) | 1. Sole power to vote or direct vote: 239,310 2. Shared power to vote or direct vote: 0 3. Sole power to dispose or direct the disposition: 239,310 4. Shared power to dispose or direct the disposition: 0 |
(c) | Starboard R GP has not entered into any transactions in the Shares since the filing of Amendment No. 8 to the Schedule 13D. The transactions in the Shares on behalf of Starboard C LP since the filing of Amendment No. 8 to the Schedule 13D are set forth in Schedule A and are incorporated herein by reference. |
F. | Starboard Value LP |
(a) | As of the close of business on April 5, 2018, 413,428 Shares were held in the Starboard Value LP Account. Starboard Value LP, as the investment manager of Starboard V&O Fund, Starboard C LP and the Starboard Value LP Account and the manager of Starboard S LLC, may be deemed the beneficial owner of the (i) 3,651,714 Shares owned by Starboard V&O Fund, (ii) 430,843 Shares owned by Starboard S LLC, (iii) 239,310 Shares owned by Starboard C LP, and (iv) 413,428 Shares held in the Starboard Value LP Account. |
Percentage: Approximately 7.5%
(b) | 1. Sole power to vote or direct vote: 4,735,295 2. Shared power to vote or direct vote: 0 3. Sole power to dispose or direct the disposition: 4,735,295 4. Shared power to dispose or direct the disposition: 0 |
(c) | The transactions in the Shares by Starboard Value LP through the Starboard Value LP Account and on behalf of each of Starboard V&O Fund, Starboard S LLC and Starboard C LP since the filing of Amendment No. 8 to the Schedule 13D are set forth in Schedule A and are incorporated herein by reference. |
G. | Starboard Value GP |
(a) | Starboard Value GP, as the general partner of Starboard Value LP, may be deemed the beneficial owner of the (i) 3,651,714 Shares owned by Starboard V&O Fund, (ii) 430,843 Shares owned by Starboard S LLC, (iii) 239,310 Shares owned by Starboard C LP, and (iv) 413,428 Shares held in the Starboard Value LP Account. |
Percentage:
Approximately 7.5%
(b) | 1. Sole power to vote or direct vote: 4,735,295 2. Shared power to vote or direct vote: 0 3. Sole power to dispose or direct the disposition: 4,735,295 4. Shared power to dispose or direct the disposition: 0 |
(c) | Starboard Value GP has not entered into any transactions in the Shares since the filing of Amendment No. 8 to the Schedule 13D. The transactions in the Shares on behalf of each of Starboard V&O Fund, Starboard S LLC, Starboard C LP and through the Starboard Value LP Account since the filing of Amendment No. 8 to the Schedule 13D are set forth in Schedule A and are incorporated herein by reference. |
17 |
Follow Assertio Therapeutics Inc (NASDAQ:ASRT)
Follow Assertio Therapeutics Inc (NASDAQ:ASRT)
Page 18 of 23 – SEC Filing
H. | Principal Co |
(a) | Principal Co, as a member of Starboard Value GP, may be deemed the beneficial owner of the (i) 3,651,714 Shares owned by Starboard V&O Fund, (ii) 430,843 Shares owned by Starboard S LLC, (iii) 239,310 Shares owned by Starboard C LP, and (iv) 413,428 Shares held in the Starboard Value LP Account. |
Percentage: Approximately 7.5%
(b) | 1. Sole power to vote or direct vote: 4,735,295 2. Shared power to vote or direct vote: 0 3. Sole power to dispose or direct the disposition: 4,735,295 4. Shared power to dispose or direct the disposition: 0 |
(c) | Principal Co has not entered into any transactions in the Shares since the filing of Amendment No. 8 to the Schedule 13D. The transactions in the Shares on behalf of each of Starboard V&O Fund, Starboard S LLC, Starboard C LP and through the Starboard Value LP Account since the filing of Amendment No. 8 to the Schedule 13D are set forth in Schedule A and are incorporated herein by reference. |
I. | Principal GP |
(a) | Principal GP, as the general partner of Principal Co, may be deemed the beneficial owner of the (i) 3,651,714 Shares owned by Starboard V&O Fund, (ii) 430,843 Shares owned by Starboard S LLC, (iii) 239,310 Shares owned by Starboard C LP, and (iv) 413,428 Shares held in the Starboard Value LP Account. |
Percentage: Approximately 7.5%
(b) | 1. Sole power to vote or direct vote: 4,735,295 2. Shared power to vote or direct vote: 0 3. Sole power to dispose or direct the disposition: 4,735,295 4. Shared power to dispose or direct the disposition: 0 |
(c) | Principal GP has not entered into any transactions in the Shares since the filing of Amendment No. 8 to the Schedule 13D. The transactions in the Shares on behalf of each of Starboard V&O Fund, Starboard S LLC, Starboard C LP and through the Starboard Value LP Account since the filing of Amendment No. 8 to the Schedule 13D are set forth in Schedule A and are incorporated herein by reference. |
J. | Messrs. Smith, Mitchell and Feld |
(a) | Each of Messrs. Smith, Mitchell and Feld, as a member of Principal GP and as a member of each of the Management Committee of Starboard Value GP and the Management Committee of Principal GP, may be deemed the beneficial owner of the (i) 3,651,714 Shares owned by Starboard V&O Fund, (ii) 430,843 Shares owned by Starboard S LLC, (iii) 239,310 Shares owned by Starboard C LP, and (iv) 413,428 Shares held in the Starboard Value LP Account. |
Percentage: Approximately 7.5%
18 |
Follow Assertio Therapeutics Inc (NASDAQ:ASRT)
Follow Assertio Therapeutics Inc (NASDAQ:ASRT)
Page 19 of 23 – SEC Filing
(b) | 1. Sole power to vote or direct vote: 0 2. Shared power to vote or direct vote: 4,735,295 3. Sole power to dispose or direct the disposition: 0 4. Shared power to dispose or direct the disposition: 4,735,295 |
(c) | None of Messrs. Smith, Mitchell or Feld has entered into any transactions in the Shares since the filing of Amendment No. 8 to the Schedule 13D. The transactions in the Shares on behalf of each of Starboard V&O Fund, Starboard S LLC, Starboard C LP and through the Starboard Value LP Account since the filing of Amendment No. 8 to the Schedule 13D are set forth in Schedule A and are incorporated herein by reference. |
K. | Mr. Molinelli |
(a) | As of the close of business on April 5, 2018, Mr. Molinelli beneficially owned 3,252 Shares. |
Percentage: Less than 1%
(b) | 1. Sole power to vote or direct vote: 3,252 2. Shared power to vote or direct vote: 0 3. Sole power to dispose or direct the disposition: 3,252 4. Shared power to dispose or direct the disposition: 0 |
(c) | Mr. Molinelli has not entered into any transactions in the Shares since the filing of Amendment No. 8 to the Schedule 13D. |
Each Reporting Person,
as a member of a “group” with the other Reporting Persons for the purposes of Section 13(d)(3) of the Securities Exchange
Act of 1934, as amended, may be deemed the beneficial owner of the Shares directly owned by the other Reporting Persons. Each
Reporting Person disclaims beneficial ownership of such Shares except to the extent of his or its pecuniary interest therein.
Item 6. | Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer. |
Item | 6 is hereby amended to add the following: |
Each of Starboard V&O
Fund, Starboard S LLC and Starboard C LP sold exchange-listed American-style call options on the dates referenced in Schedule A
referencing an aggregate of 718,200 Shares, 84,700 Shares and 47,100 Shares, respectively, which have an exercise price of $7.00
per Share and expire on May 18, 2018.
Starboard Value LP
through the Starboard Value LP Account sold in the over the counter market American-style call options on the date referenced in
Schedule A referencing an aggregate of 81,300 Shares, which have an exercise price of $7.00 per Share and expire on May 18, 2018.
As previously disclosed,
each of Starboard V&O Fund, Starboard S LLC and Starboard C LP sold exchange-listed American-style call options referencing
an aggregate of 1,267,500 Shares, 149,500 Shares and 83,000 Shares, respectively, which have an exercise price of $8.00 per Share
and expire on April 20, 2018.
19 |
Follow Assertio Therapeutics Inc (NASDAQ:ASRT)
Follow Assertio Therapeutics Inc (NASDAQ:ASRT)
Page 20 of 23 – SEC Filing
As previously disclosed,
Starboard Value LP through the Starboard Value LP Account sold in the over the counter market American-style call options referencing
an aggregate of 143,500 Shares, which have an exercise price of $8.00 per Share and expire on April 20, 2018.
As previously disclosed,
Starboard V&O Fund entered into forward purchase contracts with Morgan Stanley as the counterparty providing for the purchase
of an aggregate of 194,730 Shares (the “Forward Contracts”). The Forward Contracts have a final valuation date of May
11, 2018, however, Starboard V&O Fund has the ability to elect early settlement after serving notice to Morgan Stanley of such
intention at least two (2) scheduled trading days in advance of the desired early final valuation date. The Forward Contracts provide
for physical settlement. Until the settlement date, the Forward Contracts do not give the Reporting Persons voting and dispositive
control over the Shares to which such contracts relate.
20 |
Follow Assertio Therapeutics Inc (NASDAQ:ASRT)
Follow Assertio Therapeutics Inc (NASDAQ:ASRT)
Page 21 of 23 – SEC Filing
SIGNATURES
After reasonable inquiry
and to the best of his knowledge and belief, each of the undersigned certifies that the information set forth in this statement
is true, complete and correct.
Dated: April 5, 2018
STARBOARD VALUE AND OPPORTUNITY MASTER FUND LTD By: Starboard Value LP, its investment manager Starboard Value and Opportunity By: Starboard Value LP, its manager
Starboard Value and Opportunity By: Starboard Value R LP, its general partner STARBOARD VALUE R LP By: Starboard Value R GP LLC, its general partner STARBOARD VALUE LP By: Starboard Value GP LLC, its general partner | STARBOARD VALUE GP LLC By: Starboard Principal Co LP, its member STARBOARD PRINCIPAL CO LP By: Starboard Principal Co GP LLC, its general partner STARBOARD PRINCIPAL CO GP LLC Starboard Value R GP LLC |
By: | /s/ Jeffrey C. Smith | |
Name: | Jeffrey C. Smith | |
Title: | Authorized Signatory |
/s/ Jeffrey C. Smith |
Jeffrey C. Smith |
Individually and as attorney-in-fact for Mark R. Mitchell and Peter A. Feld |
/s/ Gavin T. |
GAVIN T. MOLINELLI |
21 |
Follow Assertio Therapeutics Inc (NASDAQ:ASRT)
Follow Assertio Therapeutics Inc (NASDAQ:ASRT)
Page 22 of 23 – SEC Filing
SCHEDULE A
Transactions in the Shares Since
the Filing of Amendment No. 8 to the Schedule 13D
Nature of the Transaction | Amount of Shares Purchased/(Sold) | Price ($) | Date of Purchase/Sale |
STARBOARD
VALUE AND OPPORTUNITY MASTER FUND LTD
Sale of Common Stock | (16,545) | 7.0221 | 03/12/2018 |
Sale of Common Stock | (2,734) | 7.0221 | 03/12/2018 |
Sale of Common Stock | (49,636) | 7.1185 | 03/13/2018 |
Sale of Common Stock | (8,201) | 7.1185 | 03/13/2018 |
Sale of Common Stock | (30,953) | 7.2387 | 03/14/2018 |
Sale of Common Stock | (5,114) | 7.2387 | 03/14/2018 |
Sale of Common Stock | (5,251) | 7.2616 | 03/15/2018 |
Sale of Common Stock | (868) | 7.2616 | 03/15/2018 |
Sale of May 2018 Call Option ($7 Strike Price) | (101,800) | 0.4000 | 04/03/2018 |
Sale of May 2018 Call Option ($7 Strike Price) | (616,400) | 0.4000 | 04/03/2018 |
Starboard
Value and Opportunity S LLC
Sale of Common Stock | (1,952) | 7.0221 | 03/12/2018 |
Sale of Common Stock | (323) | 7.0221 | 03/12/2018 |
Sale of Common Stock | (5,854) | 7.1185 | 03/13/2018 |
Sale of Common Stock | (970) | 7.1185 | 03/13/2018 |
Sale of Common Stock | (3,651) | 7.2387 | 03/14/2018 |
Sale of Common Stock | (605) | 7.2387 | 03/14/2018 |
Sale of Common Stock | (619) | 7.2616 | 03/15/2018 |
Sale of Common Stock | (103) | 7.2616 | 03/15/2018 |
Sale of May 2018 Call Option ($7 Strike Price) | (12,000) | 0.4000 | 04/03/2018 |
Sale of May 2018 Call Option ($7 Strike Price) | (72,700) | 0.4000 | 04/03/2018 |
Starboard
Value and Opportunity C LP
Sale of Common Stock | (1,085) | 7.0221 | 03/12/2018 |
Sale of Common Stock | (178) | 7.0221 | 03/12/2018 |
Sale of Common Stock | (3,256) | 7.1185 | 03/13/2018 |
Sale of Common Stock | (535) | 7.1185 | 03/13/2018 |
Sale of Common Stock | (2,030) | 7.2387 | 03/14/2018 |
Sale of Common Stock | (334) | 7.2387 | 03/14/2018 |
Follow Assertio Therapeutics Inc (NASDAQ:ASRT)
Follow Assertio Therapeutics Inc (NASDAQ:ASRT)
Page 23 of 23 – SEC Filing
Sale of Common Stock | (344) | 7.2616 | 03/15/2018 |
Sale of Common Stock | (57) | 7.2616 | 03/15/2018 |
Sale of May 2018 Call Option ($7 Strike Price) | (6,700) | 0.4000 | 04/03/2018 |
Sale of May 2018 Call Option ($7 Strike Price) | (40,400) | 0.4000 | 04/03/2018 |
STARBOARD
VALUE LP
(Through the Starboard Value LP Account)
Sale of Common Stock | (2,183) | 7.0221 | 03/12/2018 |
Sale of Common Stock | (6,548) | 7.1185 | 03/13/2018 |
Sale of Common Stock | (4,083) | 7.2387 | 03/14/2018 |
Sale of Common Stock | (693) | 7.2616 | 03/15/2018 |
Sale of May 2018 Call Option ($7 Strike Price) | (81,300) | 0.4000 | 04/03/2018 |